CATALOGO DEI PRODOTTI DELLA RICERCA

Bronte, Vincenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.329
EU - Europa 5.681
AS - Asia 1.741
OC - Oceania 15
SA - Sud America 14
AF - Africa 6
Continente sconosciuto - Info sul continente non disponibili 3
Totale 13.789
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.293
GB - Regno Unito 2.797
CN - Cina 1.350
IT - Italia 589
FR - Francia 494
IE - Irlanda 433
FI - Finlandia 409
DE - Germania 381
SE - Svezia 323
SG - Singapore 193
UA - Ucraina 131
VN - Vietnam 56
TR - Turchia 42
CA - Canada 28
BE - Belgio 27
NL - Olanda 27
HK - Hong Kong 26
KR - Corea 19
RU - Federazione Russa 18
IN - India 15
AU - Australia 12
CZ - Repubblica Ceca 11
ES - Italia 10
JP - Giappone 9
CL - Cile 6
SA - Arabia Saudita 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
AT - Austria 3
BR - Brasile 3
HU - Ungheria 3
ID - Indonesia 3
LU - Lussemburgo 3
NZ - Nuova Zelanda 3
PL - Polonia 3
RO - Romania 3
CH - Svizzera 2
CR - Costa Rica 2
EC - Ecuador 2
EG - Egitto 2
EU - Europa 2
IL - Israele 2
IR - Iran 2
JM - Giamaica 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LV - Lettonia 2
MY - Malesia 2
NG - Nigeria 2
PA - Panama 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AR - Argentina 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BO - Bolivia 1
BY - Bielorussia 1
CO - Colombia 1
GL - Groenlandia 1
HR - Croazia 1
IQ - Iraq 1
JO - Giordania 1
LB - Libano 1
MA - Marocco 1
MK - Macedonia 1
MN - Mongolia 1
MX - Messico 1
NO - Norvegia 1
OM - Oman 1
PH - Filippine 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
UZ - Uzbekistan 1
Totale 13.789
Salva come PNG Salva come JPEG
Città #
Southend 2.673
Jacksonville 1.241
Chandler 857
Woodbridge 851
Ann Arbor 635
Houston 431
Dublin 424
Ashburn 302
Verona 300
Beijing 240
Lawrence 220
Princeton 220
Wilmington 216
Nanjing 132
Shenyang 116
New York 115
Jinan 111
Singapore 108
Sindelfingen 84
Redmond 75
Hebei 66
Helsinki 65
Tianjin 61
Nanchang 55
Haikou 51
Milan 49
Ningbo 48
Hangzhou 44
Zhengzhou 42
Changsha 36
Jiaxing 35
Taizhou 34
Los Angeles 31
Seattle 31
Guangzhou 30
Norwalk 30
San Francisco 29
Dong Ket 27
Brussels 26
Boardman 25
Taiyuan 25
Toronto 24
Chicago 23
Hong Kong 22
Redwood City 22
Dearborn 20
Fuzhou 20
Falls Church 19
Seoul 19
Dongguan 18
Washington 16
Grafing 15
Fairfield 13
Amsterdam 11
Düsseldorf 11
Lanzhou 11
Auburn Hills 9
Kochi 9
San Diego 9
Cagliari 8
Cambridge 8
Munich 8
Padova 8
Bologna 6
Ferrara 6
Groningen 6
Mehlingen 6
San Giovanni Lupatoto 6
Brno 5
Clearwater 5
Großschönau 5
Isola della Scala 5
Kent 5
Shanghai 5
Tokyo 5
Canberra 4
Chions 4
Melbourne 4
Renton 4
Riva 4
Riyadh 4
Sydney 4
Tombolo 4
Trieste 4
Auckland 3
Boydton 3
Detroit 3
Gunzenhausen 3
Kemerovo 3
Lappeenranta 3
London 3
Luxembourg 3
Madrid 3
Menlo Park 3
Misterbianco 3
Noisy-le-sec 3
Novokuznetsk 3
Odesa 3
Ome 3
Ottawa 3
Totale 10.663
Salva come PNG Salva come JPEG
Nome #
IFN-gamma- Mediated Upmodulation of MHC Class I Expression Activates Tumor-Specific Immune Response in a Mouse Model of Prostate Cancer 169
IFN-gamma- Mediated Upmodulation of MHC Class I Expression Associated to a B7-1-Expressing Tumor Cell Vaccine Activates Tumor-Specific Immune Response in a Mouse Model of Prostate Cancer. 156
Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes. 131
Feasibility of telomerase-specific adoptive T-cell therapy for B-cell chronic lymphocytic leukemia and solid malignancies 121
Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma 117
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 113
Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease 112
Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. 107
Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis 105
Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3 104
Human Anti Cancer Cytokine Induced Killer Cells and TheirInteraction With the Host Immune System 102
Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy 102
MAP Kinase inhibition reshapes tumour microenvironment of mouse pancreatic cancer by depleting anti-inflammatory macrophages 102
MDSCs in cancer: Conceiving new prognostic and therapeutic targets 98
IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer 97
Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. 95
Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. 93
A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). 92
Induction of immunosuppressive functions and NF-κB by FLIP in monocytes 92
Adoptive immunotherapy of experimental tumors using cytotoxic lymphocytes to carry and deliver toxins 91
New idrosoluble furoxan derivatives having antitumoral activity 91
Nitric oxide furoxan derivative compounds endowed with antitumoral activity 91
The Emerging Immunological Role of Post-Translational Modifications by Reactive Nitrogen Species in Cancer Microenvironment 91
Interfacing polymeric scaffolds with primary pancreatic ductal adenocarcinoma cells to develop 3D cancer models. 89
Role of P2z purinergic receptors in ATP-mediated killing of tumor necrosis factor (TNF)-sensitive and TNF-resistant L929 fibroblasts. 88
IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. 87
Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. 87
Antitumour efficacy of lymphokine-activated killer cells loaded with ricin against experimentally induced lung metastases. 87
Altered macrophage differentiation and immune dysfunction in tumor development. 85
PDE5 INHIBITOR COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY 85
Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells "in vitro" and correlating with progression "in vivo" 85
Antitumor vaccination: where we stand. 84
Disabled homolog 2 controls pro-metastatic activity of tumor-associated macrophages 84
Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages 83
Unraveling the role of lymph node metastasis in PDAC and dCCA progression 83
The Endless Saga of Monocyte Diversity 82
Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. 81
Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. 80
Antigen specificity of immune suppression by myeloid-derived suppressor cells. 80
Therapeutic targeting of myeloid-derived suppressor cells. 79
Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen. 79
Deciphering the state of immune silence in fatal COVID-19 patients 79
Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. 78
Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer. 78
Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. 78
A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. 78
Responses of mouse lymphocytes to extracellular ATP. II. Extracellular ATP causes cell type-dependent lysis and DNA fragmentation. 78
Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. 77
Use of myeloid cell biomarkers for the diagnosis of cancer. 76
Gene expression profiling of human fibrocytic myeloid-derived suppressor cells (f-MDSCs) 75
IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. 75
Smoothing T cell roads to the tumor: Chemokine post-translational regulation. 75
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. 75
In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. 74
Derangement of immune responses by myeloid suppressor cells. 74
Immunocompromised tumor-bearing mice show a selective loss of STAT5a/b expression in T and B lymphocytes. 74
Adoptive transfer of lymphokine-activated killer cells loaded with 4'-deoxy-4'-iododoxorubicin: therapeutic effect in mice bearing lung metastases. 74
Resistance of lymphokine-activated T lymphocytes to cell-mediated cytotoxicity. 74
Nitric oxide affects immune cells bioenergetics: long-term effects of nitric-oxide derivatives on leukaemic Jurkat cell metabolism 74
Interaction of human pancreatic ductal adenocarcinoma cells with polymeric scaffolds to develop tissue-engineered cancer models. 74
Detection and functional evaluation of arginase-1 isolated from human PMNs and murine MDSC 74
CD66b-CD64dimCD115- cells in the human bone marrow represent neutrophil-committed progenitors 74
Role of adhesion molecules in the immune reaction to M-MSV-induced tumors. 73
Meccanismi molecolari della lisi mediata dai linfociti citotossici 73
Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression 72
Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. 71
Anatomically restricted synergistic antiviral activities of innate and adaptive immune cells in the skin. 71
Cancer Immune Modulation and Immunosuppressive Cells: Current and Future Therapeutic ApproachesNano-Oncologicals 71
Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. 71
Role of arginine metabolism in immunity and immunopathology. 70
Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention. 70
Inhibition of CTL-line lysis after gangliosides treatment. 70
Extracellular ATP as a possible mediator of cell-mediated cytotoxicity. 70
A Relay Pathway between Arginine and Tryptophan Metabolism Confers Immunosuppressive Properties on Dendritic Cells 70
Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion 69
Immunogenetic aspects of erosive osteoarthritis of the hand in patients from northern Italy. 69
Baricitinib restrains the immune dysregulation in patients with severe COVID-19 69
Bone marrow mesenchymal stromal cells induce nitric oxide synthase-dependent differentiation of CD11b+ cells that expedite hematopoietic recovery 68
The immune regulation in cancer by the amino acid metabolizing enzymes ARG and IDO. 68
Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. 68
Fatal cytokine release syndrome by an aberrant FLIP/STAT3 axis 68
Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+Monocytic Antigen-Presenting Cells in Tumors 67
Myeloid-derived suppressor cells generated in vitro 66
4PD Functionalized Dendrimers: A Flexible Tool for In Vivo Gene Silencing of Tumor-Educated Myeloid Cells 66
IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. 65
Extracellular ATP causes lysis of mouse thymocytes and activates a plasma membrane ion channel. 65
Anti-L-selectin monoclonal antibody treatment in mice enhances tumor growth by preventing CTL sensitization in peripheral lymph nodes draining the tumor area. 65
Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. 64
Interaction of large granular lymphocytes with susceptible target does not induce second messenger and cytolytic granule exocytosis. 64
Tumor cells hijack macrophages via lactic acid 64
Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer 64
Therapeutical effect of 4'-deoxy-4'-iododoxorubicin-loaded LAK cells in mice bearing lung metastases. 63
The in vivo role of leukocyte function-associated antigen-1 in cytotoxic cell activity against tumors induced by Moloney-murine sarcoma/leukemia retroviral complex. 63
Myeloid-derived suppressor cell heterogeneity in human cancers 63
mTOR and STAT3 Pathway Hyper-Activation is Associated with evated Interleukin-6 Levels in Patients with Shwachman-Diamond Syndrome: Further Evidence of Lymphoid Lineage Impairment 63
Control of immune response by amino acid metabolism. 62
Inhibition of protein tyrosine phosphorylation prevents T-cell-mediated cytotoxicity. 62
Responses of mouse lymphocytes to extracellular adenosine 5'-triphosphate (ATP). Lymphocytes with cytotoxic activity are resistant to the permeabilizing effects of ATP. 62
Arginase, nitric oxide synthase, and novel inhibitors of L-arginine metabolism 62
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. 61
Totale 8.110
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.055
article - articoli 41.679
book - libri 0
conference - conferenze 961
curatela - curatele 0
other - altro 767
patent - brevetti 1.018
selected - selezionate 0
volume - volumi 2.630
Totale 94.110
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.607 215 52 44 167 90 155 88 222 39 181 132 222
2020/20211.748 101 273 65 188 324 164 23 132 151 37 203 87
2021/20221.735 106 442 31 52 74 47 70 111 115 89 151 447
2022/20232.728 257 262 303 445 230 632 42 154 294 14 57 38
2023/20241.516 63 98 101 192 209 236 66 140 16 87 239 69
2024/202529 29 0 0 0 0 0 0 0 0 0 0 0
Totale 13.997